| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $3,274,441 ) |
| | 2025 | 2025 | BIOCORRX PHARMACEUTICALS, INC. | 2390 E ORANGEWOOD AVE STE 500 | ANAHEIM | CA | 92806-6139 | ORANGE | USA | U01DA059994 | Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD). | 000 | 2 | NIH | 1/9/2025 | $3,274,441 |
|
| Issue Date FY: 2024 ( Subtotal = $4,131,123 ) |
| | 2024 | 2024 | BIOCORRX PHARMACEUTICALS, INC. | 2390 E ORANGEWOOD AVE STE 500 | ANAHEIM | CA | 92806-6139 | ORANGE | USA | U01DA059994 | Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD). | 000 | 1 | NIH | 2/22/2024 | $4,131,123 |
| | 2024 | 2024 | BIOCORRX PHARMACEUTICALS, INC. | 2390 E ORANGEWOOD AVE STE 500 | ANAHEIM | CA | 92806-6139 | ORANGE | USA | U01DA059994 | Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD). | 002 | 1 | NIH | 7/18/2024 | $4,131,123 |
| | 2024 | 2024 | BIOCORRX PHARMACEUTICALS, INC. | 2390 E ORANGEWOOD AVE STE 500 | ANAHEIM | CA | 92806-6139 | ORANGE | USA | U01DA059994 | Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD). | 001 | 1 | NIH | 3/12/2024 | $0 |
| | 2024 | 2024 | BIOCORRX PHARMACEUTICALS, INC. | 2390 E ORANGEWOOD AVE STE 500 | ANAHEIM | CA | 92806-6139 | ORANGE | USA | U01DA059994 | Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD). | 002 | 1 | NIH | 7/18/2024 | -$4,131,123 |
|
|
